ReviewCurrent rheumatology reports2012
Control of arthritis pain with anti-nerve-growth factor: risk and benefit.
Review in Current rheumatology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Targeting Inflammatory Pathways in Chronic Low Back Pain: Opportunities for Novel Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials.Therapeutic advances in musculoskeletal disease · 2022Article
- Soluble inflammatory mediators of synoviocytes stimulated by monosodium urate crystals induce the production of oxidative stress, pain, and inflammation mediators in chondrocytes : Secretome of synoviocytes induces chondrocyte damage.Clinical rheumatology · 2021Article
- The Role of Substance P in the Regulation of Bone and Cartilage Metabolic Activity.Frontiers in endocrinology · 2020Review
- Mechanisms that drive bone pain across the lifespan.British journal of clinical pharmacology · 2019Review
- Emerging Trend in the Pharmacotherapy of Osteoarthritis.Frontiers in endocrinology · 2019Review
- Article
- The Changing Sensory and Sympathetic Innervation of the Young, Adult and Aging Mouse Femur.Neuroscience · 2018Article
- Identification of potential peripheral blood diagnostic biomarkers for patients with juvenile idiopathic arthritis by bioinformatics analysis.Rheumatology international · 2017Article
- p75 Neurotrophin Receptor in the Skin: Beyond Its Neurotrophic Function.Frontiers in medicine · 2017Review
- Anti-nerve growth factor antibody attenuates chronic morphine treatment-induced tolerance in the rat.BMC anesthesiology · 2016Article
- Current research on pharmacologic and regenerative therapies for osteoarthritis.Bone research · 2016Review
- Substance-P in symptomatic mediopatellar plica as a predictor of patellofemoral pain.Biomedical reports · 2016Article
- Calcitonin gene-related peptide in the joint: contributions to pain and inflammation.British journal of clinical pharmacology · 2015Review
- On the predictive utility of animal models of osteoarthritis.Arthritis research & therapy · 2015Review
- Suppression of Peripheral Pain by Blockade of Voltage-Gated Calcium 2.2 Channels in Nociceptors Induces RANKL and Impairs Recovery From Inflammatory Arthritis in a Mouse Model.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Identification of long noncoding RNA associated with osteoarthritis in humans.Orthopaedic surgery · 2014Article
- Painful, degenerating intervertebral discs up-regulate neurite sprouting and CGRP through nociceptive factors.Journal of cellular and molecular medicine · 2014Article
- Genes involved in the osteoarthritis process identified through genome wide expression analysis in articular cartilage; the RAAK study.PloS one · 2014Article
- The future of osteoarthritis therapeutics: emerging biological therapy.Current rheumatology reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arthritis is characterized by pain and inflammation. Recently, attention has been focused on nerve-growth factor (NGF), a neurotrophin that is a key regulator of peripheral nociception because it mediates overexpression of proinflammatory neuron-derived molecules such as substance P, serotonin, and calcitonin gene-related peptide. Antibodies have been generated for NGF and its receptor that are effective in reducing pain in preclinical pain models, and clinical trials in patients with advanced knee and hip osteoarthritis and low-back pain. Results show pain reduction is rapid and sustained. Adverse events with anti-NGF included transient paraesthesia and edema, rapidly progressive OA, and, in a small number of patients treated with both anti-NGF and nonsteroidal anti-inflammatory drugs, osteonecrosis. Inhibition of the NGF-stimulated nociceptive pathway seems to be effective; however, the adverse effects require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.